Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

NCT00328653 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Conjunctivitis, Vernal

Interventions

DRUG: Cyclosporine NOVA22007 0.05%
DRUG: Cyclosporine NOVA22007 0.1%
DRUG: Vehicle

Sponsor

Santen SAS